Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The objective of this study was to evaluate the long-term cost effectiveness of exenatide once weekly (ExQW) versus insulin glargine (IG) or liraglutide 1.2 mg (Lira1.2mg) for the treatment of adult patients with type 2 diabetes mellitus (T2DM) not adequately controlled on oral antidiabetic drug (OAD) therapy in Greece.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Drug Investig

Title: Clinical drug investigation

Publisher: Springer Science and Business Media LLC

ISSN (Electronic): 1179-1918

ISSN (Print): 1173-2563

Publication date (Electronic): Jan 2018

Volume: 38

Issue: 1

Affiliations

[1 ] Department of Health Services Organization and Management, National School of Public Health, 196 Alexandras Avenue, 11521, Athens, Greece. tzanet.haris@gmail.com.

[2 ] Department of Endocrinology and Metabolic Diseases, University of Thessaly School of Medicine, Larissa, Greece.

[3 ] Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), "Aghia Sophia" Children's Hospital, Athens, Greece.

[4 ] Department of Health Services Organization and Management, National School of Public Health, 196 Alexandras Avenue, 11521, Athens, Greece.

Article

Publisher Item ID: 10.1007/s40261-017-0586-0

DOI: 10.1007/s40261-017-0586-0

PubMed ID: 29080210

SO-VID: 7e780f57-5cde-4da4-a81b-65b6602cefdb

History

Data availability:

Comments

Comment on this article

Cited by 8

See all cited by